로딩 중…
지수 로딩 중…
젠큐릭스
229000· KOSDAQ· Health Care· Health Care Equipment & Services
₩1,954+0.72%
2026-09-14
Financials
Valuation Metrics
젠큐릭스's Market Cap is ₩458B. At end of 2025 it was ₩250B.
Investment Metrics(as of 2026-10-13)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 45.78B KRW |
| Revenue | 8.93B KRW |
| Net Income | -7.51B KRW |
| Total Assets | 31.17B KRW |
| Net Assets | 12.61B KRW |
| Employees | 68 |
| Value | |
| P/B | 3.64x |
| P/S | 5.13x |
| FCF Yield | -13.84% |
| Profitability | |
| ROE | -59.55% |
| ROA | -24.08% |
| Op. Margin | -60.44% |
| Revenue Growth | 19.67% |
| Earnings Growth | -180.89% |
| Financial Health | |
| Debt Ratio | 147.29% |
| Total Debt | 10.62B KRW |
| FCF | -6.34B KRW |
| Cash | 97.2M KRW |
| Current Ratio | 0.48x |
| Performance | |
| 1Y Return | 22.58% |
| 1M Return | 7.78% |
| From 52W High | -73.31% |
| 1Y MDD | -76.15% |
| Trading | |
| Volume | 166,331 shares |
| Trading Value | 327.3M KRW |
| Foreign Own. | 1.71% |
| Per Share | |
| EPS | -320 KRW |
| BPS | 537 KRW |
Company Info
Genecurix, established in 2011 as a liquid biopsy-based molecular diagnostic testing technology enterprise, was listed on KOSDAQ in 2020. The company has developed innovative cancer diagnostic solutions, including Asia's first breast cancer prognosis diagnosis GeneSWell BCT, Droplex, and early diagnostic tests HEPA eDX and COLO eDX. Genecurix has acquired a stake in GinoBio to commercialize cfDNA and research CTC technology, fostering collaborations with leading companies in core technological fields. Genecurix is headquartered in Guro-gu, Seoul Metropolitan City.